Pcn104 - Economic Analysis of Costs and Resource Consumption of Ixazomib in Patients With Relapsed / Refractory Multiple Myeloma in Austria

Abstract

breast (EBC/MBC) and metastatic gastric cancer (MGC) in Italy. METHODS: Drug and administration costs were included. Official, public drug prices were used for Herceptin® SC and IV, and a mandatory 20% discount was applied for all trastuzumab biosimilars. All IV trastuzumab formulations are available in 150mg vials, whereas only KANJINTI® would be available also in 420-mg vials. Drug costs were calculated for two scenarios: no vial-sharing and full vialsharing (i.e. no drug wastage). For the no vial-sharing scenario, patient weight distributions by indication were implemented accounting for optimal vial combinations to minimise drug wastage. RESULTS: KANJINTI® was shown to generate savings ranging from V1,670 to V3,358 per patient vs. SC Herceptin® across indications; V5,877 to V7,918 vs. IV Herceptin®; and V958 to V1,236 vs. other trastuzumab biosimilars in the scenario with no vial-sharing. With full vialsharing, KANJINTI® would generate savings ranging from V4,300 to V5,761 per patient vs. SC Herceptin®; V4,097 to V5,715 vs. IV Herceptin®; and no additional savings vs. other trastuzumab biosimilars. With no vial-sharing, KANJINTI® was the least costly treatment for EBC patients weighing 75 kg or less (60.25% of patients); with full vial-sharing, KANJINTI® was the least costly treatment for EBC patients weighing 89 kg or lower (87.5%). Similar results were obtained for MBC and MGC patients. CONCLUSIONS: KANJINTI® is the least costly treatment option for the vast majority of patients, with the potential to realise budget savings compared with all other trastuzumab treatment options. The availability of the 420-mg vial allows a reduction of drug wastage and the generation of further savings with biosimilars when full vial-sharing is not possible. OBJECTIVES:Multiple myeloma (MM) is a progressive, fatal cancer that affects the plasma cells. It accounts for 1% of all malignancies and 10% of all hematological cancers. In Austria, nearly 350 people are newly diagnosed every year. The nationwide, age-standardized incidence of MM for 2015 is 4.9 per 100,000 inhabitants. The aim of this cost comparison is to analyze differences in resource consumption and costs of treatment alternatives administered in different settings. Oral Ixazomib was compared with infusable Carfilzomib, Elotuzumab and Daratumumab, all in combination with Lenalidomide and Dexamethasone. Daratumumab requires premedication. METHODS: A costing model with a six month time horizon was developed from the payer's perspective in 2017 Euros. The main objective of the model was to assess differences in resource consumption (medication, personal, material, monitoring and day clinic) and related costs. In order to conduct the analysis a bottom-up micro-costing approach was carried out. Personal, material and monitoring costs were calculated based on a resource utilization survey via questionnaire. RESULTS: Total treatment costs for Ixazomib+Lenalidomide+Dexamethasone (IxLenDex) amount to 94,000 V over a time horizon of 6 months. Carfilzomi-b+Lenalidomide+Dexam...

Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany

“…The costs of AE management were similar and relatively low across all triplet therapies. However, this is in contrast with recently published data which reported that oral-based therapy is associated with relatively lower costs of AE management due to their better safety profiles [38,39]. In this study, a number of additional AEs were not taken into account as it was not possible to obtain costs from Morbi-RSA or the definitions differed across the clinical trials.…”